Affected by multiple resonances such as policies, markets, and capital, the domestic innovative drug industry has ushered in rapid development
.
According to industry forecasts, the overall domestic innovative drug market currently accounts for a very small proportion of the public drug terminal market, and there is huge room for improvement in the future
.
In this context, both leading companies such as Hengrui and Fosun, as well as emerging pharmaceutical companies such as Zai Lab and Genting Xinyao, are actively deploying in the field of innovative drugs, and the commercialization process is accelerating
.
Innovative drug industry (Photo source: Pharmaceutical Network)
Innovative drugs bring revenue growth to many pharmaceutical companies
Innovative drugs bring revenue growth to many pharmaceutical companies
Recently, it has been a concentrated period for listed pharmaceutical companies to disclose their 2022 interim performance reports.
From the annual reports of many pharmaceutical companies, it can be seen that many pharmaceutical companies have benefited from the growth of innovative drug business and obtained dazzling transcripts
.
For example, on August 23, Sino Biopharmaceutical released its 2022 semi-annual performance report
.
In the first half of the year, the company achieved double growth in revenue and net profit, reaching 15.
19 billion yuan and 1.
66 billion yuan respectively, a year-on-year increase of 5.
9% and 4.
5%, respectively
.
Among them, the revenue from innovative drugs totaled 3.
49 billion yuan, accounting for 22.
9% of the total revenue, a year-on-year increase of 14.
2%
.
The semi-annual report also disclosed that the company's innovative drug revenue will account for 24% of the total this year, and it is expected to exceed the 10 billion yuan mark by 2023
.
On August 24, Kain Technology released its 2022 semi-annual report.
The report shows that in the first half of the year, the company's revenue and net profit both increased, with an increase of 8.
77% and 5.
01%, respectively
.
During the reporting period, its self-developed Class 1 innovative drug Kailivy with independent intellectual property rights saw a year-on-year increase of 274.
48% in revenue after being included in the National Medical Insurance Catalogue, and the market steadily improved
.
Sinolink Securities also expects that Kailiwei will further expand the scope of medical insurance indications by the end of the year, and is expected to achieve further growth under the influence of favorable policies
.
In addition, many pharmaceutical companies such as Huadong Medicine and Henlius also mentioned the growth points brought by innovative drugs to the company's revenue in half a year
.
However, affected by policies such as centralized drug procurement, there are also companies whose income has declined
.
Among them, Hengrui Medicine mentioned in its semi-annual report that the company's revenue declined in the first half of this year due to the decline in revenue from centralized procurement of generic drugs and the implementation of new medical insurance negotiated prices for many innovative drugs
.
The purpose of centralized procurement is to squeeze the water of artificially high prices.
Although innovative drugs, like generic drugs, face the pressure of normalized centralized procurement, industrial opportunities and challenges coexist, and most of the pharmaceutical companies entering the market have no intention of retreating
.
Major pharmaceutical companies increase research and development, and actively deploy internationalization
Major pharmaceutical companies increase research and development, and actively deploy internationalization
It can be seen from the semi-annual report that most pharmaceutical companies are continuing to increase R&D investment and introduce scientific research talents to accelerate the deployment of innovative drugs
.
For example, Hengrui Medicine’s cumulative R&D investment in the first half of the year reached 2.
909 billion yuan, an increase of 12.
74% year-on-year, accounting for 28.
44% of sales revenue year-on-year, a record high; Kain Technology’s R&D investment also increased significantly during the reporting period, an increase of 82.
92% , and the company also actively introduced a group of talents to help the research and development of innovative drugs; Hairong Pharmaceutical's research and development expenses in the first half of the year increased by 22.
56% year-on-year, accounting for 439.
01% of operating income, and research and development investment reached a new high
.
In addition, on March 14, Hairong Pharma officially entered the Beijing Stock Exchange listing guidance period.
On June 15, the company was only transferred to the innovation layer according to the research and development standards, which is expected to accelerate the research and development of innovative drugs and the subsequent commercialization process
.
With continuous R&D investment, it is believed that these pharmaceutical companies will gradually harvest R&D results in the future
.
In addition, in order to find new growth points, local pharmaceutical companies including BeiGene, Hengrui, Zhongsheng Pharmaceutical, and Sinopharm Group have been actively deploying internationalization in recent years
.
Among them, the US market has become the first destination for many pharmaceutical companies to go out because of its huge market and high recognition of FDA certification
.
From the perspective of the way domestic drugs go abroad, some rely on borrowing boats to go overseas, that is, license out, some “marriage” with multinational pharmaceutical companies, and some rely on independent research and development to go overseas, and this is also the strength of local innovative drug companies.
proof
.
The industry believes that innovation has become the transformation and development trend of the pharmaceutical industry.
In the future, leading companies with rich R&D pipelines, faster commercialization, and active expansion of the international market are expected to gain opportunities, and with the R&D results of these pharmaceutical companies, they will form a commercial With the implementation of the transformation, profitability will also usher in a qualitative improvement
.
